サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1791567

クローニングと突然変異誘発の世界市場

Cloning and Mutagenesis

出版日
ページ情報
英文 178 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.90円
クローニングと突然変異誘発の世界市場
出版日: 2025年08月15日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 178 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

クローニングと突然変異誘発の世界市場は2030年までに103億米ドルに到達

2024年に34億米ドルと推定されるクローニングと突然変異誘発の世界市場は、2024年から2030年にかけてCAGR 20.0%で成長し、2030年には103億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるクローニングキットは、CAGR 23.2%を記録し、分析期間終了までに51億米ドルに達すると予測されます。突然変異誘発キット分野の成長率は、分析期間中CAGR19.1％と推定されます。

米国市場は推定9億650万米ドル、中国はCAGR18.7％で成長予測

米国のクローニングと突然変異誘発市場は、2024年に9億650万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに16億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは18.7%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ18.8％と16.9％と予測されています。欧州では、ドイツがCAGR約14.3%で成長すると予測されています。

世界のクローニングと突然変異誘発市場- 主要動向と促進要因のまとめ

クローニングと突然変異誘発の需要急増の原動力は？

クローニングと突然変異誘発は、バイオテクノロジー、医薬品、農業科学など様々な分野で不可欠なコンポーネントとなっています。遺伝子組み換え生物（GMO）やバイオ医薬品に対する需要の増加は、この市場の重要な促進要因となっています。ヘルスケア分野では、遺伝子治療の進歩がクローニング技術、特に再生医療や精密腫瘍学の需要を促進しています。さらに、ハイスループット・ミュータジェネシス技術の開発により、遺伝子工学の研究が大幅に加速し、機能性を強化した改変タンパク質の作製が可能になりました。がん、糖尿病、遺伝性疾患などの慢性疾患の増加により、分子生物学の研究が強化され、クローニングと突然変異誘発ツールへの投資がさらに加速しています。さらに、創薬やワクチン開拓のために遺伝物質を操作する能力は、特にmRNA技術の研究が進む中で市場の魅力を高めています。製薬会社はこれらの技術を活用して、より効果的な治療用タンパク質、抗体、遺伝子編集ソリューションを製造しており、世界中で採用が拡大しています。

テクノロジーはどのようにクローニングと突然変異誘発の未来を再構築しているのか？

CRISPR-Cas9やその他の遺伝子編集技術の進歩は、クローニングと突然変異誘発の展望に革命をもたらしました。次世代シーケンサー（NGS）の導入により、正確な遺伝子改変が可能になり、従来これらの技術に関連していた時間とコストの制約が劇的に軽減されました。自動化とAI主導のワークフローにより、研究室はより高い効率でハイスループットの突然変異誘発実験を実行できるようになり、研究や製品開発の納期を短縮できるようになりました。さらに、合成生物学とクローニングと突然変異誘発の融合は、新しい生合成経路の創出を促進し、それによってこれらの技術の応用範囲を拡大しています。タンパク質の機能を人工的に強化するために突然変異誘発を利用する、定向進化アプローチの出現は、酵素工学や工業バイオテクノロジーにおいて支持を集めています。研究者はまた、より正確な遺伝子改変を可能にし、オフターゲット効果を最小限に抑え、実験結果の信頼性を高めるために、部位特異的突然変異誘発技術の改良に注力しています。

競合情勢を形成している主な市場動向は？

市場情勢の競争は激化しており、各社は技術的優位性を得るために研究開発に多額の投資を行っています。市場拡大を牽引する重要な動向は、クローニングと突然変異誘発に特化したサービスを提供する調査受託機関（CRO）の台頭です。このシフトは特に製薬会社やバイオテクノロジー企業で顕著であり、新薬のコスト削減と市場投入までの時間短縮のために調査をアウトソーシングしています。もう一つの新たな動向は、クラウドベースのバイオインフォマティクス・プラットフォームの採用です。このプラットフォームは、研究者が突然変異誘発実験を遠隔で設計・解析することを可能にし、共同研究を促進し、データの精度を向上させる。さらに、オープンアクセス遺伝子データベースの普及により、科学者は膨大な遺伝子情報リポジトリを活用して、より多くの情報に基づいたクローニング実験を行えるようになっています。合成生物学と精密医療に対する資金提供の増加は、利害関係者がより個別化された治療介入の開発を目指す中で、さらなる技術革新に拍車をかけると予想されます。

市場拡大を促す成長要因は何か？

クローニングと突然変異誘発市場の成長は、ゲノム研究への投資の増加、創薬への応用の拡大、合成生物学の役割の拡大など、いくつかの要因によってもたらされます。製薬業界では、抗体開発やワクチン研究のための突然変異誘発への依存が、パンデミック後に強まっており、遺伝子工学ツールの採用率の上昇につながっています。さらに、害虫や過酷な環境条件に耐性を持つ遺伝子組み換え作物の創出など、農業バイオテクノロジーの進歩がクローニング技術の需要を押し上げています。組換えタンパク質やバイオ燃料のより効率的な生産の必要性も、産業バイオテクノロジーにおける高度な突然変異誘発技術の採用を後押ししています。さらに、ゲノム編集プロジェクトに対する規制当局の支援や政府の資金援助が市場拡大をさらに後押ししており、クローニングと突然変異誘発は将来の科学技術革新に不可欠な柱となっています。

セグメント

製品タイプ（クローニングキット、変異誘発キット、その他の製品タイプ）、技術（Topo PCRクローニング技術、部位特異的変異誘発技術、Blunt Endクローニング技術、シームレスクローニング技術、その他の技術）、エンドユーザー（バイオ医薬品・製薬企業エンドユーザー、CRO・CMOエンドユーザー、学術・研究機関エンドユーザー）

調査対象企業の例

  • Agilent Technologies, Inc.
  • Assay Genie
  • Bio-Rad Laboratories, Inc.
  • Bolder BioTechnology, Inc.
  • Creative Biogene
  • Danaher Corporation
  • Genes2Me
  • Genewiz（Azenta Life Sciences）
  • Genomax Technologies Pte Ltd
  • GenScript
  • Integrated DNA Technologies（IDT）
  • Jena Bioscience GmbH
  • Merck KGaA
  • New England Biolabs
  • OriGene Technologies
  • Promega Corporation
  • Takara Bio Inc.
  • Thermo Fisher Scientific, Inc.
  • TransGen Biotech Co., Ltd.
  • Vazyme

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP29999

Global Cloning and Mutagenesis Market to Reach US$10.3 Billion by 2030

The global market for Cloning and Mutagenesis estimated at US$3.4 Billion in the year 2024, is expected to reach US$10.3 Billion by 2030, growing at a CAGR of 20.0% over the analysis period 2024-2030. Cloning Kits, one of the segments analyzed in the report, is expected to record a 23.2% CAGR and reach US$5.1 Billion by the end of the analysis period. Growth in the Mutagenesis Kits segment is estimated at 19.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$906.5 Million While China is Forecast to Grow at 18.7% CAGR

The Cloning and Mutagenesis market in the U.S. is estimated at US$906.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 18.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 18.8% and 16.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.3% CAGR.

Global Cloning and Mutagenesis Market - Key Trends & Drivers Summarized

What Is Driving the Surging Demand for Cloning and Mutagenesis?

Cloning and mutagenesis have become integral components in various fields such as biotechnology, pharmaceuticals, and agricultural sciences. The increasing demand for genetically modified organisms (GMOs) and biopharmaceuticals is a crucial driver of this market. In the healthcare sector, gene therapy advancements have propelled the demand for cloning technologies, particularly for regenerative medicine and precision oncology. Furthermore, the development of high-throughput mutagenesis techniques has significantly accelerated research in genetic engineering, enabling the creation of modified proteins with enhanced functionalities. The rising prevalence of chronic diseases such as cancer, diabetes, and genetic disorders has intensified research efforts in molecular biology, further fueling investments in cloning and mutagenesis tools. Additionally, the ability to manipulate genetic material for drug discovery and vaccine development is enhancing the market’s attractiveness, particularly with the ongoing exploration of mRNA technology. Pharmaceutical companies are leveraging these technologies to produce more effective therapeutic proteins, antibodies, and gene-editing solutions, which are seeing increased adoption worldwide.

How Is Technology Reshaping the Future of Cloning and Mutagenesis?

Advancements in CRISPR-Cas9 and other gene-editing technologies have revolutionized the cloning and mutagenesis landscape. The introduction of next-generation sequencing (NGS) has enabled precise genetic modifications, drastically reducing time and cost constraints traditionally associated with these techniques. With automation and AI-driven workflows, laboratories are now able to execute high-throughput mutagenesis experiments with greater efficiency, ensuring faster turnaround times for research and product development. Moreover, the convergence of synthetic biology with cloning and mutagenesis is facilitating the creation of novel biosynthetic pathways, thereby expanding the application scope of these technologies. The emergence of directed evolution approaches, where mutagenesis is used to artificially enhance protein functions, has gained traction in enzyme engineering and industrial biotechnology. Researchers are also focusing on improving site-directed mutagenesis techniques to enable more precise genetic alterations, minimizing off-target effects and increasing reliability in experimental outcomes.

What Are the Key Market Trends That Are Shaping the Competitive Landscape?

The market landscape for cloning and mutagenesis is increasingly competitive, with companies investing heavily in research and development to gain a technological edge. A significant trend driving market expansion is the rise of contract research organizations (CROs) that provide specialized cloning and mutagenesis services. This shift is particularly notable in pharmaceutical and biotech firms, which are outsourcing research to reduce costs and accelerate time-to-market for new drugs. Another emerging trend is the adoption of cloud-based bioinformatics platforms that allow researchers to design and analyze mutagenesis experiments remotely, facilitating collaboration and improving data accuracy. Additionally, the proliferation of open-access genetic databases is enabling scientists to leverage vast genetic information repositories for more informed cloning experiments. The increasing funding for synthetic biology and precision medicine is expected to spur further innovations, as stakeholders seek to develop more personalized therapeutic interventions.

What Are the Growth Drivers Fueling Market Expansion?

The growth in the cloning and mutagenesis market is driven by several factors, including rising investments in genomic research, increasing applications in drug discovery, and the expanding role of synthetic biology. The pharmaceutical industry’s reliance on mutagenesis for antibody development and vaccine research has intensified post-pandemic, leading to higher adoption rates of genetic engineering tools. Moreover, advancements in agriculture biotechnology, such as the creation of genetically modified crops resistant to pests and harsh environmental conditions, are propelling the demand for cloning technologies. The need for more efficient production of recombinant proteins and biofuels has also driven the adoption of advanced mutagenesis techniques in industrial biotechnology. Additionally, regulatory support and government funding for genome-editing projects are further boosting market expansion, making cloning and mutagenesis an essential pillar of future scientific innovations.

SCOPE OF STUDY:

The report analyzes the Cloning and Mutagenesis market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Cloning Kits, Mutagenesis Kits, Other Product Types); Technology (Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology, Other Technologies); End-Use (Biopharmaceutical and Pharmaceutical Companies End-Use, CROs and CMOs End-Use, Academic and Research Institutes End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

  • Agilent Technologies, Inc.
  • Assay Genie
  • Bio-Rad Laboratories, Inc.
  • Bolder BioTechnology, Inc.
  • Creative Biogene
  • Danaher Corporation
  • Genes2Me
  • Genewiz (Azenta Life Sciences)
  • Genomax Technologies Pte Ltd
  • GenScript
  • Integrated DNA Technologies (IDT)
  • Jena Bioscience GmbH
  • Merck KGaA
  • New England Biolabs
  • OriGene Technologies
  • Promega Corporation
  • Takara Bio Inc.
  • Thermo Fisher Scientific, Inc.
  • TransGen Biotech Co., Ltd.
  • Vazyme

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Cloning and Mutagenesis - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Applications of Functional Genomics and Protein Engineering Propel Growth of Cloning and Mutagenesis Tools
    • Expanding Biopharmaceutical R&D Activity Drives Demand for High-Fidelity Gene Cloning and Mutagenesis Technologies
    • Advancements in Site-Directed Mutagenesis Enhance Efficiency of Precision Genetic Modifications
    • Growing Use of Recombinant DNA Technologies in Synthetic Biology Expands Adoption of Cloning Techniques
    • Increased Demand for Custom Gene Synthesis and Expression Cloning Generates Market Opportunities
    • Rapid Progress in CRISPR and Genome Editing Research Spurs Adoption of Mutagenesis Protocols
    • Integration of Automation and High-Throughput Screening Enhances Workflow Efficiency in Cloning and Mutagenesis Labs
    • Expansion of Academic and Research Institutions Globally Strengthens Demand for Gene Manipulation Kits
    • Rising Focus on Protein Structure-Function Studies Propels Market for Directed Evolution and Mutagenesis
    • Growing Biotech Startup Activity Accelerates Commercial Use of Cloning Vectors and Mutation Libraries
    • Increased Application of Mutagenesis in Vaccine Development Drives Market Growth
    • Adoption of Mutagenesis Techniques for Enzyme Optimization and Industrial Biocatalysts Expands Use Cases
    • Rising Investments in Agricultural Biotechnology Fuel Demand for Plant Gene Cloning and Trait Improvement
    • Growing Trend Toward Personalized Medicine Supports Custom Gene Editing and Cloning Solutions
    • Availability of Cloud-Based Bioinformatics Tools Enhances Adoption of Cloning and Mutagenesis Protocols
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Cloning and Mutagenesis Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Cloning and Mutagenesis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Cloning Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Cloning Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Mutagenesis Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Mutagenesis Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for CROs & CMOs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for CROs & CMOs End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Academic & Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Biopharmaceutical & Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Biopharmaceutical & Pharmaceutical Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Topo PCR Cloning Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Topo PCR Cloning Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Site-directed Mutagenesis Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Site-directed Mutagenesis Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Blunt End Cloning Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Blunt End Cloning Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Seamless Cloning Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Seamless Cloning Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Cloning and Mutagenesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 30: USA Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: USA 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
    • TABLE 34: Canada Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 36: Canada Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Canada 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
  • JAPAN
    • Cloning and Mutagenesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
    • TABLE 40: Japan Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Japan 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 42: Japan Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Japan 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
  • CHINA
    • Cloning and Mutagenesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
    • TABLE 46: China Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: China 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 48: China Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: China 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
  • EUROPE
    • Cloning and Mutagenesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for Cloning and Mutagenesis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
  • FRANCE
    • Cloning and Mutagenesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 58: France Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: France 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
    • TABLE 60: France Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: France 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
  • GERMANY
    • Cloning and Mutagenesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 64: Germany Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Germany 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
    • TABLE 66: Germany Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Germany 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
  • ITALY
    • TABLE 70: Italy Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Italy 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
    • TABLE 72: Italy Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Italy 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
  • UNITED KINGDOM
    • Cloning and Mutagenesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 76: UK Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: UK 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
    • TABLE 78: UK Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: UK 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Rest of Europe 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
    • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Rest of Europe 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Cloning and Mutagenesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Asia-Pacific 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
    • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Asia-Pacific 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 94: Rest of World Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of World 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
    • TABLE 96: Rest of World Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Rest of World 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of World 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030

IV. COMPETITION